LeMaitre Vascular, Inc.
LMATHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeLeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company carries a $1.93B market cap, placing it firmly in the small-cap category. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services.
Market Cap
$1.93B
Beta
0.47
P/E (TTM)
29.63
P/E (Fwd)
26.57
EPS (TTM)
$2.85
EPS (Fwd)
$3.18
ROE
16.8%
ROA
7.4%
Cash
$376.2M
Total Debt
$190.3M
Free CF
$49.3M
52W Change
-6.3%
Annual Financials
Cash vs Debt
Where LMAT stands vs its 150-day and 200-day moving averages
As of the October 1, 2026 close, LMAT finished 15.03% below its 150-day moving average ($97.20) and 12.32% below its 200-day moving average ($94.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LMAT overbought or oversold?
At the October 1, 2026 close, LMAT's RSI(14) was 70.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
LeMaitre Vascular, Inc. holds $376.2M in cash against $190.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $49.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 16.8% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $161.7M (2022) to $249.6M (2025), reflecting a 54% increase over the period.
The relatively low beta of 0.47 suggests LMAT is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LMAT.